{"id":963694,"date":"2026-05-15T16:09:50","date_gmt":"2026-05-15T20:09:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-reports-first-quarter-2026-financial-results-provides-corporate-update-announces-cfo-transition\/"},"modified":"2026-05-15T16:09:50","modified_gmt":"2026-05-15T20:09:50","slug":"rani-therapeutics-reports-first-quarter-2026-financial-results-provides-corporate-update-announces-cfo-transition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-reports-first-quarter-2026-financial-results-provides-corporate-update-announces-cfo-transition\/","title":{"rendered":"Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition"},"content":{"rendered":"
\n

\n – Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill\u00ae for the treatment of obesity in collaboration with ProGen \u2013<\/em>\n <\/p>\n

\n – Appointed Alireza Javadi, Ph.D. as Chief Technical Officer –<\/em>\n <\/p>\n

\n – Appointed Jesper H\u00f8iland as Head of Strategy and Dr. Sara Kenkare-Mitra as a Strategic Advisor \u2013<\/em>\n <\/p>\n

SAN JOSE, Calif., May 15, 2026 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d; \u201cRani\u201d or \u201cCompany\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the first quarter ended March 31, 2026, provided a corporate update, and announced a Chief Financial Officer transition.<\/p>\n

\u201cIn the first quarter of 2026, we strengthened the strategic and scientific foundation of Rani by welcoming two exceptional industry leaders while continuing to advance our lead metabolic program,\u201d said Talat Imran, Chief Executive Officer of Rani Therapeutics. \u201cThe appointments of Jesper H\u00f8iland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor bring decades of global experience in drug development, commercialization, and portfolio prioritization, expertise that will be instrumental as we evaluate new opportunities for the RaniPill\u00ae platform and focus our pipeline on programs with the greatest clinical and commercial potential. Their insights come at an important time, as we continue progressing our ongoing Phase 1 trial of RT-114, our first obesity program in the clinic, an oral GLP-1\/GLP-2 dual agonist through our partnership with ProGen. With this strengthened leadership and the continued advancement of RT-114, we believe Rani is well-positioned to execute on our 2026 priorities and continue unlocking the potential of oral biologics for patients.\u201d<\/p>\n

Rani also today announced that Svai Sanford, Chief Financial Officer, has decided to pursue another professional opportunity and will transition from his role following the appointment of a successor. Mr. Sanford will continue to serve as Chief Financial Officer during a transition period to ensure continuity and support an orderly handover of responsibilities.<\/p>\n

During his tenure, Mr. Sanford played a central role in the Company\u2019s financial evolution, including leading the Company through its initial public offering and helping establish a strong financial foundation. He also supported multiple financing initiatives and the expansion of the Company\u2019s investor base, positioning the Company with a solid balance sheet and a diversified group of long-term shareholders.<\/p>\n

\u201cSvai has been a key leader during a period of significant transformation for the Company,\u201d said Talat Imran, CEO. \u201cHis leadership through the IPO and subsequent financing efforts strengthened our financial position and set the Company up well for its next phase of growth. We are grateful for his contributions and appreciate his commitment to supporting a smooth transition.\u201d<\/p>\n

Mr. Sanford\u2019s departure is not the result of any disagreement with the Company on any matter relating to the Company’s financial operations, policies or practices.<\/p>\n

\u201cI\u2019m proud of what we\u2019ve accomplished together,\u201d said Mr. Sanford. \u201cLeading the Company through the IPO and helping to bring in high-quality investors was a meaningful experience. With the Company on strong financial footing, this felt like the right time for me to pursue another opportunity. I look forward to supporting the team during the transition and seeing the Company continue to succeed.\u201d<\/p>\n

The Company has commenced a search for a successor Chief Financial Officer. Mr. Sanford is expected to remain involved during the transition period to help ensure stability, continuity, and momentum across financial and operational priorities.<\/p>\n

\n First Quarter 2026 Highlights:<\/strong>\n <\/p>\n